Early markers of renal dysfunction in patients with sickle cell/β-thalassemia
Ersi Voskaridou(Laiko General Hospital of Athens), Ioannis Papassotiriou(National and Kapodistrian University of Athens), D. Simirloglou(Laiko General Hospital of Athens), Evangelos Terpos(National and Kapodistrian University of Athens), Nektarios Anagnostopoulos(National and Kapodistrian University of Athens), Eugenia Hantzi(Children's Hospital Agia Sophia), Dimitris Loukopoulos(Biomedical Research Foundation of the Academy of Athens), Spiridon Michail(Laiko General Hospital of Athens), Alexandra Margeli(National and Kapodistrian University of Athens)
Cited by 76
Related Papers
Hematological findings and complications of <scp>COVID</scp>‐19
|American Journal of Hematology|2020|1.7k
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
|The Lancet Oncology|2019|493
Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group
|Journal of Clinical Oncology|2010|409
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
|Leukemia|2017|356
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320